161 related articles for article (PubMed ID: 23532741)
1. Infusion of bevacizumab increases the risk of intestinal perforation: results on a series of 143 patients consecutively treated.
Borzomati D; Nappo G; Valeri S; Vincenzi B; Ripetti V; Coppola R
Updates Surg; 2013 Jun; 65(2):121-4. PubMed ID: 23532741
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab-induced perforation of the gastrointestinal tract: clinical and radiographic findings in 11 patients.
Borofsky SE; Levine MS; Rubesin SE; Tanyi JL; Chu CS; Lev-Toaff AS
Abdom Imaging; 2013 Apr; 38(2):265-72. PubMed ID: 22627832
[TBL] [Abstract][Full Text] [Related]
3. First description of an uterine perforation potentially imputable to treatment with bevacizumab.
Uguen T; Leconte B; Desgrippes R; Tchoundeu B; Bretagne JF; Manfredi S
Acta Oncol; 2012 Nov; 51(8):1102-4. PubMed ID: 23020310
[No Abstract] [Full Text] [Related]
4. Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study.
Kabbinavar FF; Flynn PJ; Kozloff M; Ashby MA; Sing A; Barr CE; Grothey A
Eur J Cancer; 2012 May; 48(8):1126-32. PubMed ID: 22424880
[TBL] [Abstract][Full Text] [Related]
5. Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers.
Abu-Hejleh T; Mezhir JJ; Goodheart MJ; Halfdanarson TR
Curr Oncol Rep; 2012 Aug; 14(4):277-84. PubMed ID: 22532266
[TBL] [Abstract][Full Text] [Related]
6. Colonic perforation with intraluminal stents and bevacizumab in advanced colorectal cancer: retrospective case series and literature review.
Imbulgoda A; MacLean A; Heine J; Drolet S; Vickers MM
Can J Surg; 2015 Jun; 58(3):167-71. PubMed ID: 25799132
[TBL] [Abstract][Full Text] [Related]
7. The feasibility of a short bevacizumab infusion in patients with metastatic colorectal cancer.
Terazawa T; Nishitani H; Kato K; Hashimoto H; Akiyoshi K; Iwasa S; Nakajima TE; Hamaguchi T; Yamada Y; Shimada Y
Anticancer Res; 2014 Feb; 34(2):1053-6. PubMed ID: 24511054
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab 5 or 7.5 mg/kg in metastatic colorectal cancer can be infused safely over 10 minutes.
Mahfoud T; Tanz R; Mesmoudi M; Khmamouche MR; Bazine A; Aassab R; Ismaili N; Boutayeb S; Ichou M; Errihani H
J Gastrointest Cancer; 2012 Jun; 43(2):244-8. PubMed ID: 21197622
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer.
Akun E; Okutur K; Seber S; Korkmaz T; Aydin K; Bozkurt M; Namal E; Hasbal B; Tecimer C; Demir G
J BUON; 2012; 17(4):669-76. PubMed ID: 23335523
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation.
Tol J; Cats A; Mol L; Koopman M; Bos MM; van der Hoeven JJ; Antonini NF; van Krieken JH; Punt CJ
Invest New Drugs; 2008 Aug; 26(4):393-7. PubMed ID: 18335169
[TBL] [Abstract][Full Text] [Related]
11. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management.
Heinzerling JH; Huerta S
Curr Surg; 2006; 63(5):334-7. PubMed ID: 16971205
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab.
Roohullah A; Wong HL; Sjoquist KM; Gibbs P; Field K; Tran B; Shapiro J; Mckendrick J; Yip D; Nott L; Gebski V; Ng W; Chua W; Price T; Tebbutt N; Chantrill L
World J Gastroenterol; 2015 May; 21(17):5352-8. PubMed ID: 25954110
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups.
Qi WX; Shen Z; Tang LN; Yao Y
Eur J Clin Pharmacol; 2014 Aug; 70(8):893-906. PubMed ID: 24858820
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab-induced bowel perforation.
Sliesoraitis S; Tawfik B
J Am Osteopath Assoc; 2011 Jul; 111(7):437-41. PubMed ID: 21803880
[TBL] [Abstract][Full Text] [Related]
15. Bleeding after bevacizumab treatment in patients with metastatic colorectal cancer.
Cao D; Guo CH; Liu JW; Yang X; Li Q
Tumori; 2015; 101(1):46-51. PubMed ID: 25702674
[TBL] [Abstract][Full Text] [Related]
16. [Surgical management of bevacizumab-associated peritonitis due to perforation].
Kube R; Meyer F; Bien N; Schmidt C; Mroczkowski P; Dalicho S; Lippert H
Zentralbl Chir; 2009 Sep; 134(5):462-7. PubMed ID: 19757347
[TBL] [Abstract][Full Text] [Related]
17. GI perforation associated with bevacizumab.
Yoon SS; Rivera R; Shah A; Ozden N
Gastrointest Endosc; 2012 Jun; 75(6):1286-7. PubMed ID: 21862004
[No Abstract] [Full Text] [Related]
18. Bevacizumab-based therapy and complication risk after colonic stent placement: is it time for a warning?
Fuccio L; Cennamo V
Gastrointest Endosc; 2010 Dec; 72(6):1330; author reply 1330-2. PubMed ID: 21111886
[No Abstract] [Full Text] [Related]
19. Bevacizumab-associated fistula formation in postoperative colorectal cancer patients.
Ganapathi AM; Westmoreland T; Tyler D; Mantyh CR
J Am Coll Surg; 2012 Apr; 214(4):582-8; discussion 588-90. PubMed ID: 22321523
[TBL] [Abstract][Full Text] [Related]
20. Pneumothorax after bevacizumab-containing chemotherapy: a case report.
Yang SH; Lin JK; Chen WS; Lin TC; Yang SH; Jiang JK; Chang SC; Lan YT; Chao TC; Yen CC; Tzeng CH; Teng HW
Jpn J Clin Oncol; 2011 Feb; 41(2):269-71. PubMed ID: 21030401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
